United Therapeutics CORP 8-K filings

United Therapeutics reported a 2% revenue decrease to $783.3 million for Q2 2026, but saw net income rise 8% to $333.0 million, driven by strong EPS growth and strategic advancements in rare disease treatments and organ manufacturing.

United Therapeutics Corporation announced the appointment of Victor Dzau, M.D., to its Board of Directors, effective July 22, 2026, to enhance its mission in developing transplantable organs and organ alternatives.

United Therapeutics Corporation shareholders approved the 2026 Stock Incentive Plan, replacing the prior plan and authorizing new share grants.

United Therapeutics reported a 2% year-over-year revenue decrease for Q1 2026, totaling $781.5 million, but highlighted positive clinical trial results and strategic development plans.

Nebulized Tyvaso met TETON-1’s primary endpoint in idiopathic pulmonary fibrosis with a 130.1 mL FVC benefit vs placebo and a reduced risk of clinical worsening; an FDA priority-review sNDA is planned by summer 2026.

United Therapeutics announced positive results from its phase 3 ADVANCE OUTCOMES study of ralinepag, showing a 55% reduction in clinical worsening risk for pulmonary arterial hypertension patients.

United Therapeutics Corporation announced record full year 2025 revenues of $3.18 billion, an 11% increase over 2024, driven by strong performance in its Tyvaso product line.

United Therapeutics Corporation announced the appointment of Dr. Kevin J. Tracey to its Board of Directors and approved amendments to its bylaws, effective January 21, 2026.

United Therapeutics Corporation announced record financial results for the third quarter of 2025, driven by strong revenue growth in key products and promising clinical trial data.

United Therapeutics announced positive TETON-2 study results for Tyvaso in idiopathic pulmonary fibrosis, meeting its primary endpoint and showing benefits across subgroups.

United Therapeutics Corporation announced the initiation of a $1 billion accelerated share repurchase program, reflecting confidence in its stock value and future growth.

United Therapeutics Corporation announced record second quarter 2025 financial results, driven by double-digit revenue growth across key products, and authorized a new $1 billion share repurchase program.

United Therapeutics Corporation announced that its shareholders approved an amendment and restatement of the 2015 Stock Incentive Plan, increasing the shares available for awards and extending its expiration, alongside the election of all twelve director nominees and other proposals at its 2025 Annual Meeting.

United Therapeutics announced a 17% year-over-year increase in total revenue for Q1 2025, reaching $794.4 million, driven primarily by growth in Tyvaso sales.

United Therapeutics Corporation has entered into a new $2.5 billion credit agreement, replacing its 2022 facility and providing funds for working capital and general corporate purposes.

United Therapeutics Corporation announced record full year 2024 revenues of $2.88 billion, a 24% increase over 2023, driven primarily by growth in Tyvaso sales.

United Therapeutics presented an overview of its business strategy, pipeline progress, and financial strength at the 43rd annual J.P. Morgan Healthcare Conference.

United Therapeutics announced a 23 percent year-over-year revenue increase in the third quarter of 2024, reaching $748.9 million.

United Therapeutics announced a 20 percent year-over-year increase in total revenue for the second quarter of 2024, reaching $714.9 million.

United Therapeutics Corporation shareholders approved an amendment to the 2015 Stock Incentive Plan and elected Jan Malcolm to the Board of Directors at the 2024 Annual Meeting.

United Therapeutics announced a 34% year-over-year increase in total revenue for the first quarter of 2024, reaching $677.7 million.

United Therapeutics Corporation has successfully extended the maturity date of its existing credit facilities to March 31, 2029.

United Therapeutics has authorized a $1 billion share repurchase program, reflecting confidence in its financial position and future prospects.

United Therapeutics has filed a motion for a preliminary injunction against Liquidia, alleging patent infringement related to Liquidia's efforts to gain approval for a pulmonary hypertension associated with interstitial lung disease (PH-ILD) indication for its inhaled treprostinil product.

United Therapeutics announced record full-year revenue of $2.33 billion for 2023 and has filed a lawsuit against the FDA regarding a competitor's drug application.